Eric Rowinsky, MD
Consultant Chief Medical Officer

Over 30 years of experience in oncology drug development.

CMO, Hummingbird Biotherapeutics, Inc.

Former Head of R&D at Stemline Therapeutics, Inc.

Former EVP and CMO of ImClone Systems (acquired by Eli Lilly).

Former Director of the Institute of Drug Development, San Antonio Texas and Clinical Professor of Medicine, University of Texas, San Antonio

Former Associate Professor of Oncology at the Johns Hopkins University School of Medicine

MD from the Vanderbilt University School of Medicine

US based